The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial

[1]  M. Konstam,et al.  Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials , 2016, Circulation. Heart failure.

[2]  Daniel G. MacArthur,et al.  The ExAC browser: displaying reference data information from over 60 000 exomes , 2016, bioRxiv.

[3]  Akshay S. Desai,et al.  Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial , 2016, The Lancet.

[4]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[5]  O. Havndrup,et al.  Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[6]  E. Antman,et al.  Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. , 2015, JACC. Heart failure.

[7]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[8]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[9]  G. Felker,et al.  Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). , 2014, JACC. Heart failure.

[10]  S. Abbara,et al.  Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. , 2013, JACC. Heart failure.

[11]  R. Kwong,et al.  T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular imaging.

[12]  G. Koch,et al.  Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials: Analyzing Data Using a Global Method , 2012, Circulation. Heart failure.

[13]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[14]  R. Foley,et al.  Kidney function reference values in US adolescents: National Health And Nutrition Examination Survey 1999-2008. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[15]  J. Seidman,et al.  Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. , 2011, Circulation research.

[16]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[17]  Roger R Markwald,et al.  Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. , 2010, The Journal of clinical investigation.

[18]  S. Colan,et al.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.

[19]  Arantxa González,et al.  Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases , 2010, Circulation.

[20]  B. Maron,et al.  Echocardiographic Strain Imaging to Assess Early and Late Consequences of Sarcomere Mutations in Hypertrophic Cardiomyopathy , 2009, Circulation. Cardiovascular genetics.

[21]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[22]  M. Penicka,et al.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. , 2009, The Journal of molecular diagnostics : JMD.

[23]  K. Ohtomo,et al.  A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. , 2007, International heart journal.

[24]  G. Church,et al.  Polony Multiplex Analysis of Gene Expression (PMAGE) in Mouse Hypertrophic Cardiomyopathy , 2007, Science.

[25]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[26]  C. Mady,et al.  Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. , 2005, The American journal of cardiology.

[27]  J. Varni,et al.  The PedsQL™ as a pediatric patient-reported outcome: reliability and validity of the PedsQL™ Measurement Model in 25,000 children , 2005, Expert review of pharmacoeconomics & outcomes research.

[28]  S. Seto,et al.  Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[29]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[30]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.

[31]  B. Maron.  Sudden death in young athletes. , 1980, The New England journal of medicine.

[32]  Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study , 1996 .

[33]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.